Whitehawk Therapeutics Secures $87.5 Million Through PIPE Financing for Cancer Research Advancement

Whitehawk Therapeutics Secures $87.5 Million in Private Placement Financing

MORRISTOWN, N.J. — May 13, 2026 — Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), a pioneering company in the clinical-stage oncology therapeutics sector, has announced a significant financial stride with the completion of a $87.5 million private placement equity financing. This funding round is expected to propel the company’s innovative cancer treatment initiatives further, particularly focusing on their advanced antibody drug conjugate (ADC) therapies.

This private investment in public equity (PIPE) financing has attracted participation from several esteemed institutional investors, including Avoro Capital, QVT, and Coastlands Capital, along with support from members of the company’s executive team. Such diversified backing highlights the confidence the investment community has in Whitehawk’s future.

According to the securities purchase agreement, Whitehawk will sell approximately 4.3 million shares of common stock at a price of $3.92 per share, along with pre-funded warrants for an additional 18 million shares of common stock at a purchase price of $3.9199. The exercise price for these warrants is set at a minimal $0.0001 per share. The closure of the PIPE financing is anticipated for May 14, 2026, pending standard closing conditions.

Utilization of Proceeds

The net proceeds from this financing are expected to be utilized for overall working capital and corporate purposes, which includes pivotal advancements in Whitehawk’s ADC pipeline and the relative research and development activities. This infusion of capital is also projected to extend the company’s cash runway into the latter part of 2028, ensuring continued progress in its mission to create impactful treatments for patients battling challenging cancers.

Industry Context

Whitehawk Therapeutics is at the forefront of cancer research, applying cutting-edge scientific techniques to existing tumor biology. Their current portfolio, which is notably robust with three innovative ADC assets, aims to overcome the limitations observed in earlier generations of cancer treatments. These assets have been in-licensed from WuXi Biologics, under an exclusive agreement for development and global commercialization, showcasing Whitehawk’s commitment to forging strategic partnerships that enhance its therapeutic pipeline.

The implications of such financing extend beyond just monetary gains. This funding not only empowers Whitehawk to press ahead with its clinical trials but also signals to the market the potential advancements that await in the oncology landscape. The company is currently positioned to face numerous challengers head-on while exploring new opportunities for enhanced cancer care.

Looking Ahead

The announcement of this PIPE financing comes at a critical time as the biotech sector faces uncertainties, particularly regarding market conditions and geopolitical challenges. Whitehawk's management has expressed cautious optimism, emphasizing the importance of flexibility and responsiveness in adapting to changing environments.

In a recent statement, Whitehawk’s executives remarked on the positive reception of their strategies and the potential for significant breakthroughs in cancer therapeutics, aligned with the expectations set forth in the forward-looking statements included in their communications. It is noteworthy that these statements carry inherent risks and uncertainties, including potential market volatility and the unpredictability of clinical trial outcomes.

Conclusion

Whitehawk Therapeutics stands ready to navigate the coming years with a fortified financial framework, setting the stage for innovative treatment options in the oncology field. The journey ahead promises both challenges and opportunities, and Whitehawk is poised to make strides that may significantly transform cancer therapy as we know it.

Forward-Looking Statements: All forward-looking statements in this communication are subject to various risks and uncertainties, and readers are encouraged to review Whitehawk’s previous financial reports and adherent risk factors to gain a comprehensive understanding.

For more information about Whitehawk Therapeutics, including updates on their clinical trials and ADC developments, please visit their official website.